Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 40,000
- Avg volume
- —
- Day's range
- $28.25 – $28.25
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company operates through two segments: Healthcare Services and Diagnostic Services. Its Healthcare Services include outpatient and inpatient care; dental care, mental health care, orthopedics, preventive plans and sports, and wellness; other services, including non-medical related services, such as sports membe...
Show more
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company operates through two segments: Healthcare Services and Diagnostic Services. Its Healthcare Services include outpatient and inpatient care; dental care, mental health care, orthopedics, preventive plans and sports, and wellness; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness; hospital care; and preventive care services. The company's Diagnostic Services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. It serves corporate, individuals, and public sector clients. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.
- Industry
- Medical Care Facilities
- Sector
- Healthcare
- Phone
- 46 8 40 01 76 00
- Website
- https://www.medicover.com
- Address
- Riddargatan 12A, PO Box 5283, Stockholm, Sweden
Latest news
No headlines yet.